Dihydropyrimidinones as potent anticancer agents : Insight into the structure-activity relationship
© 2023 Deutsche Pharmazeutische Gesellschaft..
Cancer is a serious disease that has been around for a long time but currently has no sustainable solution. Several medications currently available offer an opportunity for the manifestation of cancer treatment; however, the "search for better" has led to the development and study of a variety of new scaffolds. Dihydropyrimidinones (DHPMs) are a privileged scaffold, prominent for their versatile range of biological activities. In recent years, the anticancer potential of these unsaturated pyrimidine ring systems has been traversed, along with their synthesis methods and the interlinked mechanisms leading to the anticancer activity. This review summarizes the structure-activity relationship of DHPMs as potential anticancer agents. This study is a short review of their synthesis, mechanism of action, and structure-activity relationships (SARs) that are answerable for the anticancer activity of DHPMs and have been thoroughly researched and assessed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:356 |
|---|---|
| Enthalten in: |
Archiv der Pharmazie - 356(2023), 6 vom: 21. Juni, Seite e2200664 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prasad, Tanya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticancer agents |
|---|
| Anmerkungen: |
Date Completed 05.06.2023 Date Revised 05.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ardp.202200664 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354483366 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354483366 | ||
| 003 | DE-627 | ||
| 005 | 20231226062323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ardp.202200664 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354483366 | ||
| 035 | |a (NLM)36942985 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prasad, Tanya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dihydropyrimidinones as potent anticancer agents |b Insight into the structure-activity relationship |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.06.2023 | ||
| 500 | |a Date Revised 05.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Deutsche Pharmazeutische Gesellschaft. | ||
| 520 | |a Cancer is a serious disease that has been around for a long time but currently has no sustainable solution. Several medications currently available offer an opportunity for the manifestation of cancer treatment; however, the "search for better" has led to the development and study of a variety of new scaffolds. Dihydropyrimidinones (DHPMs) are a privileged scaffold, prominent for their versatile range of biological activities. In recent years, the anticancer potential of these unsaturated pyrimidine ring systems has been traversed, along with their synthesis methods and the interlinked mechanisms leading to the anticancer activity. This review summarizes the structure-activity relationship of DHPMs as potential anticancer agents. This study is a short review of their synthesis, mechanism of action, and structure-activity relationships (SARs) that are answerable for the anticancer activity of DHPMs and have been thoroughly researched and assessed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a anticancer agents | |
| 650 | 4 | |a dihydropyrimidinones (DHPMs) | |
| 650 | 4 | |a structure-activity relationship | |
| 650 | 4 | |a synthesis | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Mahapatra, Aastha |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Tripti |e verfasserin |4 aut | |
| 700 | 1 | |a Sahoo, Chita R |e verfasserin |4 aut | |
| 700 | 1 | |a Padhy, Rabindra Nath |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archiv der Pharmazie |d 1972 |g 356(2023), 6 vom: 21. Juni, Seite e2200664 |w (DE-627)NLM000013323 |x 1521-4184 |7 nnns |
| 773 | 1 | 8 | |g volume:356 |g year:2023 |g number:6 |g day:21 |g month:06 |g pages:e2200664 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ardp.202200664 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 356 |j 2023 |e 6 |b 21 |c 06 |h e2200664 | ||